Request Demo

Last update 18 Jul 2026

Descartes-08

Last update 18 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Autologous CAR-T, mRNA CAR-T

Synonyms

Anti-BCMA CAR-T cell therapy, Anti-BCMA chimeric antigen receptor T cell therapy, autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen

+ [2]

Target

BCMA

Action

inhibitors

Mechanism

BCMA inhibitors(B-cell maturation protein inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [3]

Active Indication

Myasthenia GravisAntisynthetase SyndromeDermatomyositis+ [1]

Inactive Indication

Multiple MyelomaSystemic Lupus Erythematosus

Originator Organization

Cartesian Therapeutics, Inc.

Active Organization

Cartesian Therapeutics, Inc.

Inactive Organization-

License Organization

Cartesian Therapeutics, Inc.

Chengdu Weisijin Biopharmaceutical Technology Co., Ltd.

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Regenerative Medicine Advanced Therapy (United States)

Clinical Trials associated with Descartes-08

NCT07391605

/ RecruitingPhase 2

A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome

This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).

Start Date28 Apr 2026

Sponsor / Collaborator

Cartesian Therapeutics, Inc.

NCT07089121

/ RecruitingPhase 1/2

Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

Start Date14 Jan 2026

Sponsor / Collaborator

Cartesian Therapeutics, Inc.

NCT06799247

/ RecruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)

The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.

Start Date06 May 2025

Sponsor / Collaborator

Cartesian Therapeutics, Inc.

100 Clinical Results associated with Descartes-08

100 Translational Medicine associated with Descartes-08

100 Patents (Medical) associated with Descartes-08

Literatures (Medical) associated with Descartes-08

01 Mar 2026·NATURE MEDICINE

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

Article

Author: Slanksy, Adam ; Gwathmey, Kelly ; Siddiqi, Zaeem ; Miljkovic, Milos D ; Stewart, C Andrew ; Jewell, Christopher M ; Karam, Chafic ; Fedak, Renee R ; Kalayoglu, Murat ; Durmus, Hacer ; Sahagian, Gregory ; Shroff, Sheetal ; Kamboh, Hafsa ; Singer, Michael ; Howard, James F ; Badruddoja, Michael A ; Vu, Tuan ; Barnett-Tapia, Carolina ; Pasnoor, Mamatha ; Peltier, Amanda ; Mozaffar, Tahseen ; Vullaganti, Mithila ; Rivner, Michael ; Ragole, Thomas ; Kurtoglu, Metin ; Ruggerie, Rachel N ; Feinberg, Marc H ; Small, George ; Myers, Bennett ; Dimachkie, Mazen

Myasthenia gravis (MG) is driven by the secretion of autoantibodies from pathogenic B cell maturation antigen (BCMA)-expressing plasma cells. In this phase 2b randomized, controlled, double-blind trial, we evaluated Descartes-08, an autologous BCMA-directed mRNA chimeric antigen receptor T cell therapy, in patients with generalized MG (gMG). Patients (n = 26) were randomly allocated to receive once-weekly intravenous infusions of Descartes-08 (n = 15) or placebo (n = 11) over 6 weeks. The primary endpoint was a ≥5-point improvement in the MG Composite (MGC) score at month 3. Secondary endpoints included the mean change from baseline in MGC, MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) scores by month 12. At month 3, the proportion of patients achieving a ≥5-point improvement in the MGC score was significantly higher for those treated with Descartes-08 compared to placebo in the overall population (66.7% (n = 10/15) versus 27.3% (n = 3/11), P = 0.0472) and in a subpopulation of those positive for autoantibodies to the acetylcholine receptor (63.6% (n = 7/11) versus 12.5% (n = 1/8), P = 0.0258). For patients treated with Descartes-08, the changes from baseline in mean MGC, MG-ADL and QMG scores at month 4 were -7.1, -5.5 and -4.8, respectively, with 83.0% of patients achieving a sustained and clinically meaningful response at month 12. Notably, 33.0% of patients achieved minimum symptom expression (MSE) (MG-ADL score ≤1) by month 6, which was sustained through month 12. Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment. Descartes-08 was generally safe and well tolerated. Infusion-related reactions were the most common adverse events reported (Descartes-08, 80.0% (n = 16/20); placebo, 56.3% (n = 9/16)). In summary, a single course of six once-weekly infusions of Descartes-08 was well tolerated and resulted in sustained clinically meaningful responses among patients with gMG. ClinicalTrials.gov identifier: NCT04146051 .

01 Mar 2026·NATURE MEDICINE

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

Article

Author: Yu, David J. L. ; Mozaffar, Tahseen ; Peltier, Amanda ; Bodansky, Aaron ; Vullaganti, Mithila ; DeMaria, Gabrielle ; Fedak, Renee R. ; Siddiqi, Zaeem ; Myers, Bennett ; Kalayoglu, Murat V. ; Garcia, Samantha T. ; Curvino, Elizabeth J. ; Filev, Atanas ; Karafin, Matthew ; Rivner, Michael ; Zorn, Kelsey C. ; Mendoza, Meg ; Shaw, Jessica ; Biaksangi, Jennifer ; Gwathmey, Kelly ; Xu, Heng ; Durmuş, Hacer ; Miljković, Miloš D. ; Ragole, Thomas ; Sahagian, Gregory ; Cheng, Catherine ; Pasnoor, Mamatha ; Benson, Albina ; Badruddoja, Michael A. ; Requena, Naraly ; Ruggerie, Rachel N. ; Small, George ; Singer, Michael S. ; Quesnell, Tara ; Park, Yara A. ; Jewell, Christopher M. ; Karam, Chafic ; Shan, Yufei ; Trunnell, Amy ; Brunn, Carsten ; Vu, Tuan ; English, Adam ; Barnett-Tapia, Carolina ; Shroff, Sheetal ; Davis, Darnell ; Anderson, Mark S. ; Ngo-Casi, Minhtran ; Duvernay, Matthew T. ; Chopra, Manisha ; Feinberg, Marc H. ; Pope, Chad A. ; Habib, Ali A. ; Zhang, Yi ; DeRisi, Joseph L. ; Buensuceso, Charito ; Schneider, Dina ; Kamboh, Hafsa ; Tostanoski, Lisa H. ; de Sousa, Juliana F. ; Howard, James F. ; Traub, Rebecca E. ; Kurtoglu, Metin ; Irannejad, Mona ; Daniel, Shaji ; English, Emily P. ; Holley, Kelly ; Grover, Natalie S. ; Stewart, C. Andrew ; Slanksy, Adam

Chimeric antigen receptor (CAR)-T cell therapies have the potential to transform treatment of autoimmune disease by resetting the immune system. However, adoption of cell therapies in the autoimmune space is limited by hurdles such as inpatient administration, lymphodepletion and safety concerns around cytokine release syndrome and non-specific immunosuppression. RNA-based cell therapy has potential to address these limitations. Here we report prespecified exploratory analyses from a successful placebo-controlled, double-blind, randomized phase 2b trial in patients with generalized myasthenia gravis who received Descartes-08, an autologous, RNA-encoded anti-B cell maturation antigen (BCMA) CAR-T cell therapy. In 66.7% of patients (n = 10/15), transient targeting of BCMA with Descartes-08 administered in an outpatient setting without lymphodepletion resulted in durable clinical efficacy. Comparison of Descartes-08-treated (n ≤ 19) and placebo (n ≤ 15) cohorts by flow cytometry, serum profiling, multiplexing cytokine analysis and bulk/single-cell transcriptional analysis reveals a precision retuning of self-reactivity demonstrated by increased pro-immune function, decreased activity of BCMA⁺ plasma cells and plasmacytoid dendritic cells and reductions in disease-associated cytokines, such as IL-6. Furthermore, antibody and T cell receptor analysis revealed altered circulating repertoires of self-reactive antibodies and T cell clones among Descartes-08 participants. These effects occurred without immune suppression, indicated by the lack of decline in vaccine-specific antibodies or hypogammaglobulinemia. Our findings unveil a new type of immune reset and support the development of BCMA-targeted RNA cell therapies as a more accessible therapy for autoimmune diseases. ClinicalTrials.gov identifier: NCT04146051 .

01 Jul 2023·The Lancet. Neurology

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Article

Author: Miloš D Miljković ; Adam Chowdhury ; Marc H Feinberg ; Christopher M. Jewell ; Yufei Shan ; Beverly Mackanzie Brooks ; Matthew T. Duvernay ; Naraly Requena ; Metin Kurtoglu ; Kelly Holley ; Christopher M Jewell ; Maria Kireeva ; Mehmet Tosun ; Adam D. Slansky ; Ali Aamer Habib ; Tuan Vu ; Manisha Chopra ; Michael S Singer ; Marc H. Feinberg ; April Tenorio ; Gabrielle DeMaria ; James F Howard ; Denise Pereira ; Diana Dimitrova ; James F. Howard ; Michael Benatar ; C Andrew Stewart ; Krishna Komanduri ; Maria Elena Paredes ; Jerrica Farias ; Nizar Chahin ; Murat V Kalayoglu ; Julie Steele ; Tahseen Mozaffar ; Cara Benjamin ; Hafsa Kamboh ; Gregory Sahagian ; Minhtran Ngo Casi ; Emily English ; Volkan Granit ; Shaji Daniel ; Luis De La Cruz ; Julia Kimberly Fong ; Adam Slansky ; Niraja Suresh

BACKGROUND:

Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)-rather than the conventional DNA approach-to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells.

METHODS:

MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III-IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II-IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051.

FINDINGS:

We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3-9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were -6 (95% CI -9 to -3) for MG-ADL score, -7 (-11 to -3) for Quantitative Myasthenia Gravis score, -14 (-19 to -9) for Myasthenia Gravis Composite score, and -9 (-15 to -3) for Myasthenia Gravis Quality of Life 15-revised score.

INTERPRETATION:

In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases.

FUNDING:

Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

News (Medical) associated with Descartes-08

02 Jul 2026

·www.globenewswire.com

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on July 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on July 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X. Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Relationsmegan.leduc@cartesiantx.com Media Contact:David RosenArgot Partnersdavid.rosen@argotpartners.com

Cell TherapyPhase 2Phase 3Immunotherapy

02 Jul 2026

·www.biospace.com

Cartesian Therapeutics Announces New Employment Inducement Grants - July 2, 2026

FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on July 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on July 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit or follow the Company on LinkedIn or X . Contact Information: Investor Contact: Megan LeDuc Associate Director, Investor Relations megan.leduc@cartesiantx.com Media Contact: David Rosen Argot Partners david.rosen@argotpartners.com

14 Jun 2026

·www.biospace.com

Cartesian Therapeutics Announces New Employment Inducement Grant - June 12, 2026

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On June 8, 2026, the Company issued to this employee an option to purchase an aggregate of 6,100 shares of the Company’s common stock with an exercise price of $5.86, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 8, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the option will be fully vested on June 8, 2030. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit or follow the Company on LinkedIn or X . Contact Information: Investor Contact: Megan LeDuc Associate Director, Investor Relations megan.leduc@cartesiantx.com Media Contact: David Rosen Argot Partners david.rosen@argotpartners.com

Cell TherapyPhase 2Phase 3

100 Deals associated with Descartes-08

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myasthenia Gravis	Phase 3	United States	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	Canada	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	Italy	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	Poland	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	Serbia	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	Spain	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	Turkey	Cartesian Therapeutics, Inc.	06 May 2025
Myasthenia Gravis	Phase 3	United Kingdom	Cartesian Therapeutics, Inc.	06 May 2025
Antisynthetase Syndrome	Phase 2	United States	Cartesian Therapeutics, Inc.	28 Apr 2026
Dermatomyositis	Phase 2	United States	Cartesian Therapeutics, Inc.	28 Apr 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04146051 (Pubmed \| Nat Med)	Phase 2	Myasthenia Gravis BCMA	30	Descartes-08	oawjxtjuil(roniawnaai) = xqosytkzhp qzmsaxxoik (mmxbhmsgdm )	Positive	09 Jan 2026
NCT04146051 (Company_Website) Manual	Phase 2	Myasthenia Gravis	36	Descartes-08	nnnhxaqstn(dbnbyiveod) = sksoivfizj wfgogrwaqo (hmtohnqxob, 1.1) View more	Positive	08 Apr 2025
NCT04146051 (Company_Website) Manual	Phase 2	Myasthenia Gravis	36	Descartes-08 (without prior biologic therapies)	nnnhxaqstn(dbnbyiveod) = exyvcotbak wfgogrwaqo (hmtohnqxob, 1.5) View more	Positive	08 Apr 2025
NCT04146051 (MG-001, Neurology \| AAN2025) Manual	Phase 2	Myasthenia Gravis	31	Descartes-08	mcddymwfif(owvezqrqlx) = iidsvgqpbs qclnwnqvlj (yqnasubnvo ) View more	Positive	07 Apr 2025
NCT04146051 (MG-001, Neurology \| AAN2025) Manual	Phase 2	Myasthenia Gravis	31	Placebo	mcddymwfif(owvezqrqlx) = kkpmptnxjt qclnwnqvlj (yqnasubnvo ) View more	Positive	07 Apr 2025
NCT04146051 (Company_Website) Manual	Phase 2	Myasthenia Gravis	36	Descartes-08	glkjljsobl(ghamosyxms) = xafyumqsdx hcpblixacs (xetrstvzzk ) View more	Positive	03 Dec 2024
NCT04146051 (Company_Website) Manual	Phase 2	Myasthenia Gravis	36	Descartes-08 (without prior exposure to biologic therapies)	glkjljsobl(ghamosyxms) = qjkzgsciyw hcpblixacs (xetrstvzzk ) View more	Positive	03 Dec 2024
NCT04816526 (CTgov)	Phase 2	Multiple Myeloma	13	Descartes 08	lzrlrtalko = mydjfpxmvd xgvhokakli (vygjbtofhn, ebtlvmrbfa - oveysxngqp) View more	-	08 Oct 2024
NCT04146051 (Biospace) Manual	Phase 2	Myasthenia Gravis	36	Descartes-08	clgwncvtbs(ojwtqsscdt) = dholqozjdy bmdcfqrsvt (cxpkhoxhci ) Met View more	Positive	02 Jul 2024
NCT04146051 (Biospace) Manual	Phase 2	Myasthenia Gravis	36	Placebo	clgwncvtbs(ojwtqsscdt) = tctkgmjvwv bmdcfqrsvt (cxpkhoxhci ) Met View more	Positive	02 Jul 2024
Corporate Publications Manual	Phase 2	Myasthenia Gravis	7	Descartes-08	nbtftagosl(nqurgvkdre) = vvyhjucquq zpdjfzrkkc (fqywhgphzc ) View more	Positive	08 Jan 2024
NCT04146051 (MG-001, Pubmed 1 \| Pubmed 2 \| Lancet Neurol) Manual	Phase 1/2	Myasthenia Gravis	14	Descartes-08	trviyvfmna(psvyjnpmxh) = pltzxfsduo tvozdfziiq (kfepyzzhtw ) View more	Positive	01 Jul 2023
NCT04146051 (Corporate Publications) Manual	Phase 1/2	Myasthenia Gravis	2	Descartes 08	aopsjxaqvz(eegshexnmb) = over 50% three months after Descartes-08 administration. mrqlesccbz (kwtflqispp )	Positive	10 May 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Descartes-08

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation